Overbrook Management Corp Reduces Position in Johnson & Johnson (NYSE:JNJ)

Overbrook Management Corp cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 55.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,845 shares of the company’s stock after selling 3,610 shares during the period. Overbrook Management Corp’s holdings in Johnson & Johnson were worth $411,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. IFS Advisors LLC boosted its stake in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the period. Highline Wealth Partners LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth about $31,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth about $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the period. Finally, Activest Wealth Management purchased a new stake in Johnson & Johnson in the 3rd quarter valued at about $40,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 1.9 %

NYSE JNJ opened at $145.39 on Thursday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market cap of $350.04 billion, a PE ratio of 21.04, a price-to-earnings-growth ratio of 2.50 and a beta of 0.51. The company has a 50 day moving average price of $148.26 and a 200 day moving average price of $156.12. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22,438,500 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 9.95 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.41%. Johnson & Johnson’s payout ratio is 71.78%.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on JNJ shares. Wolfe Research started coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Royal Bank of Canada boosted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Finally, StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, January 17th. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $173.27.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.